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ABSTRACT
Direct oral anticoagulants (DOACs) have emerged 
as primary therapeutic option for stroke prevention 
in patients with atrial fibrillation. However, patients 
may have ischaemic stroke despite DOAC therapy 
and there is uncertainty whether those patients can 
safely receive intravenous thrombolysis or mechanical 
thrombectomy. In this review, we summarise and discuss 
current knowledge about different approaches to select 
patient. Time since last DOAC intake—as a surrogate 
for anticoagulant activity—is easy to use but limited 
by interindividual variability of drug pharmacokinetics 
and long cut- offs (>48 hours). Measuring anticoagulant 
activity using drug- specific coagulation assays showed 
promising safety results. Large proportion of patients 
at low anticoagulant activity seem to be potentially 
treatable but there remains uncertainty about exact safe 
cut- off values and limited assay availability. The use of 
specific reversal agents (ie, idarucizumab or andexanet 
alfa) prior to thrombolysis is a new emerging option 
with first data reporting safety but issues including 
health economics need to be elucidated. Mechanical 
thrombectomy appears to be safe without any specific 
selection criteria applied. In patients on DOAC therapy 
with large vessel occlusion, decision for intravenous 
thrombolysis should not delay thrombectomy (eg, direct 
thrombectomy or immediate transfer to a thrombectomy- 
capable centre recommended). Precision medicine 
using a tailored approach combining clinicoradiological 
information (ie, penumbra and vessel status), 
anticoagulant activity and use of specific reversal agents 
only if necessary seems a reasonable choice.
INTRODUCTION
Oral anticoagulation using direct oral anticoagu-
lants (DOACs) has emerged as the primary ther-
apeutic option for stroke prevention in patients 
with non- valvular atrial fibrillation. Furthermore, 
DOACs are used for treatment of other vascular 
diseases (ie, intracardiac thrombus, stable coro-
nary heart disease, venous thrombosis) and trials 
assessing further indications (ie, patent foramen 
ovale) are ongoing. However, patients may have 
ischaemic stroke despite DOAC therapy1 and recent 
reports found up to 13% of all patients who had a 
stroke to be on anticoagulant therapy prior to stroke 
onset with rapidly increasing numbers of DOAC.2 
Intravenous thrombolysis (IVT) and mechanical 
thrombectomy are the cornerstones of acute stroke 
therapy to reduce morbidity and improve func-
tional outcome.3 4 Acute recanalisation therapies 
bear the risk of haemorrhagic transformation of 
the infarcted brain tissue leading to symptomatic 
intracranial haemorrhage. The rate of symptom-
atic intracranial haemorrhage ranges between 3.7% 
(IVT only),5 5.1% (mechanical thrombectomy with 
thrombolysis)6 and 4.3% (mechanical thrombec-
tomy alone).7
In contrast to therapy with vitamin K antagonists 
(VKAs) which result in a broad, long lasting unse-
lected inhibition of the coagulation cascade by inhi-
bition of the proper synthesis of several coagulation 
factors (factors II, VII, IX und X), DOACs directly 
target selected factors in the coagulation cascade, 
either thrombin (dabigatran) or factor Xa (apix-
aban, rivaroxaban and edoxaban). Onset of the anti-
coagulatory effect of DOACs is quick (peak levels 
between 2 and 5 hours after intake) and last only 
for several hours to a few days. Measuring DOAC 
activity is challenging8 and there are currently no 
point- of- care devices approved for DOAC measure-
ment. In contrast, monitoring anticoagulant activity 
in patients taking VKA using point- of- care inter-
national normalised ratio (INR) testing is easy and 
results are rapidly available.9 Among patients with 
DOAC having a stroke, approximately 28% are 
potentially eligible for IVT (within 4.5 hours time 
window, National Institutes of Health Stroke Scale 
(NIHSS)≥4).10
In analogy to thrombolysis in patients on VKA, 
current approaches to select patients on DOAC 
treatment for recanalisation therapies try to identify 
those patients at low anticoagulant activity to mini-
mise the risk of symptomatic intracranial haemor-
rhage. Indeed, pioneering studies11–14 found that 
DOAC therapy does not seem to increase the risk 
of symptomatic intracranial haemorrhage following 
IVT in such selected patients. Despite this, there 
remains uncertainty among stroke physicians on 
how to select such patients. Indeed, in a multi-
centre German registry study only 6% of patients 
on DOACs eligible for thrombolysis received such 
treatment with DOAC therapy being the reason to 
withhold thrombolysis in most cases.8 In a Swiss 
study, only 15% of potentially eligible patients with 
atrial fibrillation on DOAC therapy received throm-
bolysis but there seemed to be no barrier to the 
use of mechanical thrombectomy.8 Reflecting the 
still limited evidence, the American Heart/Stroke 
Association guidelines do not make strong recom-
mendations on the use of IVT in patients taking 
DOAC, in fact they state intravenous alteplase may 
even be harmful unless routine labs or Xa activity 
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are normal or the patient has not taken a dose in >48 hours.15 
Recent approval of targeted reversal agents for dabigatran (idaru-
cizumab) and apixaban/rivaroxaban (andexanet alfa) offers a 
new, unprecedented additional option.
In this review, we recapitulate the current understanding of 
haemorrhagic transformation in acute ischaemic stroke and the 
role of thrombin, the major treatment target of DOACs, in this 
process. We present current concepts of patient selection in 
those taking DOAC and summarise available data for different 
approaches. Finally, we summarise data on mechanical throm-
bectomy in patients taking DOAC and whether specific patient 
selection is warranted.
PATHOPHYSIOLOGY, CLASSIFICATION AND THE ROLE OF 
THROMBIN IN HAEMORRHAGIC TRANSFORMATION AFTER 
ACUTE ISCHAEMIC STROKE
Haemorrhagic transformation of infarcted brain tissue may 
occur spontaneously after acute ischaemic stroke but acute reca-
nalisation therapies increase the risk. The spectrum of haem-
orrhagic transformation ranges from scattered small petechiae 
to large parenchymal bleeding with substantive mass effect 
(figure 1). Usually, haemorrhagic transformation is classified 
according to radioclinical criteria developed for large thrombol-
ysis trials (European Cooperative Acute Stroke Study /National 
Institute of Neurological Disorders and Stroke Trial) using CT 
imaging and associated worsening of the neurological function 
(measured using the NIHSS) ranging from haemorrhagic infarc-
tion to symptomatic intracerebral haemorrhage (sICH). sICH is 
associated with substantial mortality and morbidity.
The pathophysiology leading to haemorrhagic transformation 
is complex. Disruption of the blood–brain barrier increasing 
vascular permeability plays a major role in haemorrhagic trans-
formation.16 The effect of therapeutic anticoagulation on haem-
orrhagic transformation is probably mediated by increasing the 
amount of blood extravasation into the infarcted tissue due to 
reduced blood clotting rather than a direct negative effect on 
the blood–brain barrier. However, increased thrombin genera-
tion during acute ischaemic stroke has toxic effects resulting in 
blood–brain barrier leakage.17 Thrombin inhibition in rodent 
models exhibits a protective effect on the blood–brain barrier 
and reduced haemorrhagic transformation.18 DOACs either act 
as direct thrombin inhibitor (dabigatran) or inhibit thrombin 
generation from prothrombin by inhibiting the action of 
activated factor X (apixaban, edoxaban, rivaroxaban). Interest-
ingly, a recent phase- II randomised controlled trial assessing the 
adjunctive use of a direct thrombin inhibitor (agatroban) in addi-
tion to IVT shows no increase in the risk of sICH.19
VKA, by reducing the amount of factor VII available for 
interaction with tissue factor (the key system in the initiation 
of coagulation),20 reduces the extrinsic coagulation pathway and 
subsequent fibrin formation. DOACs do not affect the initial factor 
VII and VIIa interaction with tissue factor. In rodent models of 
acute ischaemic stroke and thrombolysis, VKA increased haem-
orrhagic transformation21 whereas dabigatran and rivaroxaban 
did not increase the risk after thrombolysis in rodent models.22 23 
In all these experiments, DOAC plasma levels were kept within 
the expected range during standard therapy (ie, corresponding 
<400 ng/mL in humans). Taken together, there is evidence from 
animal models that therapeutic anticoagulation with VKA but 
not DOACs increases the risk of haemorrhagic transformation 
after ischaemic stroke probably mediated trough the different 
mode of action and the pivotal role of thrombin inhibition by 
DOACs. Nevertheless, as direct translation of animal data to 
human patients is not possible, cautious approaches for clinical 
practice are warranted.
DRUG MONITORING IN DOACS
Assessing anticoagulant activity in DOACs in the emergency 
setting (in analogy to patients taking VKA) is fundamental but 
not straight forward.24 Difficulties include test availability and 
turn- around time, lack of clear cut- off values and test vari-
ability. Conventional, unspecific tests (ie, INR, activated partial 
thrombin time (aPTT), thrombin time (TT)) along with drug- 
specific tests have been used to monitor DOAC activity.24
Recent systematic reviews24 and the latest International 
Committee for Standardization in Haematology and Interna-
tional Committee on Thrombosis and Haemostasis recom-
mendations25 can be summarised as follows: (1) prothrombine 
time (PT)/INR and aPTT are not reliable tests to assess DOAC 
concentration, (2) current non- specific point of care testing 
lacks responsiveness to detect DOAC presence and (3) tandem 
mass spectrometry remains the gold standard; however, drug- 
calibrated dilute thrombin time, ecarin chromogenic assay, 
ecarin clotting time, anti- FIIa and anti- FXa are suitable for rapid 
quantitation of DOACs.
Although not recommended, some information can be derived 
from unspecific coagulation tests: a normal TT can rule out rele-
vant concentrations of dabigatran.26 Anti- Xa inhibitors show 
some degree of correlation with aPTT and PT/INR; however, 
results are hampered by overall poor correlations, significant 
reagent dependent sensitivities and variability within assays.26 
Studies in patients with acute stroke show similar results with 
normal aPTT and INR in 11%–44% of patients with peak 
DOAC drug levels.8
Mass spectrometry measurements are considered the gold 
standard as drug- specific assays for DOAC measurement25 but it 
is unsuitable for emergency situation. Outside of mass spectrom-
etry, only ecarin clotting time (for dabigatran) and calibrated 
anti- Xa assays (for Xa- inhibitors) show linear correlations to 
serum levels in a dose- dependent fashion.26 These assays have 
been used to safely guide thrombolysis and thrombectomy but 
are largely based on expert opinion and pilot safety data.27–29
Turnaround time of specific assays is improving. In centres 
where these assays are used for selection of patients for throm-
bolysis, results can be available as soon as within 30 min.29 There 
are several new approaches (including urine dipstick and a 
Figure 1 Haemorrhagic transformation on CT ranging from 
haemorrhagic infaction type I (HI1) to parenchymal haemorrhage type 
2 (PH2). Haemorrhagic transformation can occur outside the infarcted 
brain tissue (‘remote haemorrhage’). Left part of each pair CT is the initial 
perfusion imaging showing infarct core (red) and penumbra (green), and 
the right part is the postreperfusion CT.
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modification of thromboelastography testing incorporating an 
anti- Xa assay and an ecarin clotting time into a cartridge) but 
their relevance in acute stroke care is currently not clear. Most 
promising, an investigator led prospective study investigating 
a point of care DOAC device ( ClinicalTrials. gov Identifier: 
NCT02825394) has recently been completed and publication of 
the final results is eagerly awaited. Bed- side testing of relevant 
concentrations >30 ng/mL has shown acceptable sensitivity and 
specificity for rivaroxaban and edoxaban, as well as dabigatran, 
by using the Hemochron Signature Elite system.2 Finally, as prior 
studies found that Roche CoaguChek showed good calibration 
with one DOAC (rivaroxaban)30, it seems that the manufacturer 
is currently working on an evidence- based extension claim.
Lastly, the availability of these specific tests is very limited with 
only 1.5% and 22% of Australasia and North America coagula-
tion laboratories having access, respectively.31 32 However, 18 of 
the 20 certified stroke units in Switzerland have access to specific 
tests for patients who had a stroke with comparable safety results 
and treatment metrics.33
PATIENT SELECTION AND CURRENT GUIDELINE 
RECOMMENDATIONS
Different approaches have been proposed including time since 
last DOAC intake,34 drug monitoring using unspecific (ie, 
INR)2 30 or drug- specific coagulation assays (ie, DOAC plasma 
levels)28 or the use of specific reversal agents (ie, idarucizumab 
for dabigatran and andexanet alfa for factor Xa inhibitors)35–37 
to neutralise DOAC activity. Table 1 provides an overview on 
different DOACs and their characteristics.
Current guideline recommendations from national and inter-
national associations differ significantly in their conclusions (see 
table 2). The Japanese consensus statement recommends the 
use of recombinant tissue Plasminogen Activator (rt- PA) with a 
dosage of 0.6 mg/kg according to local guidelines.38
NON-SELECTIVE APPROACH TO IVT
There is a considerable number of case reports on patients 
receiving thrombolysis for acute ischaemic stroke despite being 
on DOAC therapy (over 40 case reports with >50 patients) 
with 3 patients having sICH after thrombolysis which has been 
summarised in a recent review.39 However, case reports are 
subject of selection and publication bias. Furthermore, general 
laboratory coagulation profile appeared to be part of eligibility 
assessment in several studies but the approach to selection 
was often not clearly reported. Table 3 provides an overview 
on available observational data including all studies with more 
than five patients on DOAC (first paragraph ‘heterogeneous or 
unknown selectin criteria’: 5 studies with 475 patients). In a 
Japanese national cohort, 76 patients on DOACs received IVT 
(15 also had additional mechanical thrombectomy) without any 
Table 1 Characteristics of different direct oral anticoagulants
  Dabigatran Rivaroxaban Apixaban Edoxaban
Half- life 13 hours 5–13 hours 12 hours 12 hours
Time to peak 1.5–3 hours 2–3 hours 3–4 hours 1–2 hours
Oral bio- availability 3%–7% 80%–100% 50% 60%
Renal clearance 80% 70% 45% 50%
Conventional tests Normal thrombin time=no dabigatran circulating. Other 
tests not useful.
Not useful Not useful Not useful
Suggested assays Dilute thrombin time or ecarin- based clotting assays Calibrated anti- Xa assays Calibrated anti- Xa assays Calibrated anti- Xa assays
Reversal agents Idarucizumab (approved for use prior to urgent 
interventions)
Andexanet alfa
(no approval for urgent interventions)
(Andexanet alfa not yet 
approved)
Table 2 
American Heart/Stroke Association65 The use of intravenous alteplase in patients taking direct thrombin inhibitors or direct factor Xa inhibitors has not been firmly 
established but may be harmful. Intravenous alteplase should not be administered to patients taking direct thrombin inhibitors 
or direct factor
Xa inhibitors unless laboratory tests such as aPTT, INR, platelet count, ecarin clotting time, thrombin time or appropriate direct 
factor Xa activity assays are normal or the patient has not received a dose of these agents for >48 hours (assuming normal 
renal metabolising function).
Japanese consensus statement38 For dabigatran IVT is not recommended if aPTT >1.5 times or last dose is <4 hours. In this case, IVT can be considered after 
intravenous administration of idarucizumab.
For factor Xa inhibitors IVT is not recommended if INR exceeds at least 1.7.
IVT is not recommended if the time of the last dose is <4 hours
IVT can be considered if the time of the last dose is ≥4 hours and the level of INR is ≤1.7).
IVT after emergent reversal of prolonged INR using antidotes for other anticoagulants is not recommended.
ESO Karolinska Stroke Update 201866 Patients with acute ischaemic stroke under VKA or DOAC treatment with proven large vessel occlusion should be offered IVT (if 
feasible) and endovascular treatment (thrombectomy).
Thrombolysis allowed if DOAC plasma levels <30 ng/mL
If no DOAC plasma levels available, INR measurement using Hemochron Signature Elite is possible under specific circumstances
French Society of Vascular Neurology40 IVT if no intake >48 hours or DOAC level <50 ng/mL.
Conventional testing with TT, aPTT, PT and anti- Xa levels may be used (DOAC dependant). In the case of Dabigatran, reversal 




Comparable to French Society of Vascular Neurology
aPTT, activated partial thrombin time; DOAC, direct oral anticoagulant; INR, international normalised ratio; IVT, intravenous thrombolysis; PT, prothrombine time; TT, thrombin 
time; VKA, vitamin K antagonist.
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sICH within 24 hours of treatment.10 In this cohort, IVT with 
rt- PA was used with a dosage of 0.6 mg/kg. Similarly, in the Get 
With the Guidelines Stroke registry, the sICH rate was 4.8% 
(12 patients from 251 patients on DOACs who received IVT). 
However, time since last DOAC intake was up to 7 days in this 
study.12 An international collaboration of European and Japa-
nese stroke centres published data of 78 DOAC patients (rivar-
oxaban=47) treated with IVT. Although nearly half (23/47) of 
the rivaroxaban patients recommended for IVT on the basis of 
low plasma rivaroxaban level (<100 ng/mL),11 many patients 
were selected using different approaches and no conclusion 
about one single selection criterion can be drawn from this 
study. The overall reported rate of sICH in this study was 2% (2 
patients) and none of the patients selected using DOAC plasma 
levels had sICH. Data from the Swiss Stroke Registry of 69 
patients on DOACs receiving IVT found no increased risk of 
sICH compared with patients without anticoagulation and those 
on VKAs with INR ≤1.733 (18 of 23 centres used DOAC plasma 
levels for patient selection).
SELECTION BY TIME SINCE LAST INTAKE
The predictable pharmacokinetics and dynamics of DOACs 
(table 1) has made time since last intake the basis of most 
guidance for patient selection although based on limited 
evidence.11 34 40 Time since last dose of greater than 48 hours has 
generally been considered a safe time frame for intervention as 
this represents approximately four half- lives. However, evidence 
suggests time since last intake can be a poor correlate for drug 
activity measured on admission in patients who had a stroke 
using a drug- specific coagulation assay.41 Furthermore, intrinsic 
(age, renal function, genetic polymorphisms) and extrinsic (drug 
interactions and metabolism) factors together with drug dosage 
(once daily vs twice daily) all lead to large interperson variability 
in DOACs plasma concentrations.26 42 Four small observational 
studies suggest recanalisation therapies (both IVT and endovas-
cular) may be safe in patients taking DOACs within 48 hours 
of stroke but total numbers are small and subgroup analysis 
(time from last drug intake 0–4 hours, 5–12, 12–24 etc) not 
possible.11 43–45
SELECTION OF PATIENTS BY DRUG MONITORING
Table 3 summarises observational studies applying DOAC 
plasma levels to select patients for thrombolysis (middle para-
graph, ‘DOAC plasma level based approach’: 3 studies with 36 
patients). However, prior to reviewing the evidence, one needs to 
understand the complexities in the interpretation of drug moni-
toring in DOACs (see section on drug monitoring of DOACs).
A single centre study from Basel (Switzerland) reported 
IVT in 18 patients on rivaroxaban (3 with additional mechan-
ical thrombectomy) using a standard operating procedure 
with predefined cut- offs for thrombolysis. IVT was given in 
patients with low (<20 ng/mL) or intermediate (20–100 ng/
mL) levels of rivaroxaban and prior ingestion within 48 hours.28 
There were no patients with sICH or systemic haemorrhage. 
A single- centre study from Erlangen (Germany) similarly used 
predefined plasma DOAC levels for all four available DOACs 
in determining whether patients were eligible (level <50 ng/mL) 
or potentially eligible (50–100 ng/mL) for IVT.46 In this report, 
24 DOAC (apixaban 9, dabigatran 9, rivaroxaban 6) patients 
received IVT with 1 case (4.2%) of sICH developing in a patient 
who also had mechanical thrombectomy. In both studies, the 
median turn- around time for DOAC plasma levels (ie, time 
from blood sampling to first results) was 39 and 37 min, respec-
tively.28 46 In a German multicentre study, among 150 potentially 
eligible patients, only 9 patients received IVT based on DOAC 
plasma levels without any sICH.8 Although measuring DOAC 
Table 3 Observational studies including patients on direct oral anticoagulant (DOAC) treated with intravenous thrombolysis
Study




Number of patients 
(comparator) Number of sICH/rate Comment
Heterogenous or unknown selection criteria (n=5 studies, n=475 patients)
  Xian et al12 251 (all DOAC) 12 (4.8%) 1500 (VKA) 73 (4.9%) No selection criteria or information on 
anticoagulation available
  Seiffge et al11 78 (all DOAC) 2 (3.9%) 441 (VKA) and 8938 (no 
anticoagulation)
9.3% and 7.2% Heterogenous selection criteria, all within 
48 hours, partly plasma level- based
  Suzuki et al10 71 (all DOAC) 2% n/a n/a National survey and case collection, 
(dosage of rt- PA: 0.6 mg/kg)
  Shahjouei et al14 6 (dabigatran) 0 n/a n/a Case collection
  Meinel et al33 69 (all DOAC) 3.1% 1544 (no anticoagulation) and 
156 (VKA with INR <1.7)
3.6% (no) and 4.6% (VKA) 18 of 23 centres used DOAC plasma levels 
for patient selection
DOAC plasma- level based approach (n=3 studies, n=36 patients)
  Marsch et al46 9 (all DOAC) 1 (4.2%) 31 VKA 1 (3.3%) All patients <48 hours of last intake
  Seiffge et al28 18 (rivaroxaban) 0 n/a n/a   
  Purrucker et al8 9 (all DOAC) 0 n/a n/a   
Idarucizumab (n=8 studies, n=236 patients)
  Beharry et al 13 (dabigatran) 0 n/a n/a Tenecteplase
  Barber et al 51 (dabigatran) 2 (3.9%) 1285 (all non- DOA) 49 (3.8%)   
  Kermer et al 80 (dabigatran) 0 n/a     
  Küpper et al 7 (dabigatran) 0 n/a     
  Pretnar Oblak et al 11 (dabigatran) 2sICH (18.2%) n/a no 9 with elevated thrombin time
  Giannandrea et al 55 (dabigatran) 3 sICH (5.5%) n/a n/a   
  Sanak et al 13 (dabigatran) 1 sICH (7.6%)
2 aICH
n/a n/a   
  Fang et al 6 (dabigatran) 0 n/a n/a   
INR, international normalised ratio; sICH, symptomatic intracerebral haemorrhage; VKA, vitamin K antagonist.
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plasma levels is theoretically time consuming, if blood is drawn 
directly on admission and analysis started immediately, this can 
be done in parallel to other tasks (obtaining NIHSS, neuroim-
aging). Therefore, in centres who use this approach in routine, 
door- to- needle times in patients selected using plasma levels are 
reasonable28 29 46 47 (eg, 37–48 min) and not significantly delayed 
compared with patients on VKAs.48 Point- of- care testing using 
CoaguCheck to rapidly detect <30 ng/mL (for rivaroxaban30) 
takes only less than 1 min.
USE OF SPECIFIC REVERSAL AGENTS PRIOR TO ACUTE 
TREATMENT
There are three known reversal agents to DOACs, two available 
(idarucizumab and andexant alfa) and one under development 
(and not part of this review).
Idarucizumab is a humanised monoclonal antibody fragment 
with 350 times the affinity for dabigatran than dabigatran has for 
thrombin. Andexanet alfa is a recombinant human FXa variant 
which has an affinity to anti- Xa medications similar to native Xa 
itself, serving as a decoy. Both medications have been shown to 
reverse DOAC activity in a dose- dependent manner from phase 
2 trials and have been used in single arm, unblinded observa-
tional studies in patients with major bleeding49 or major bleeding 
or need for urgent intervention with return to normal drug- 
specific activity measures (ie, anti- Xa activity) parameters within 
minutes.50 Idarucizumab has been approved by the European 
Medical Agency in 2015 to reverse dabigatran and andexanet 
alfa received conditional approval in 03/2019 for reversing rivar-
oxaban and apixaban (edoxaban not yet approved, preliminary 
data available51). While andexanet alfa has not been approved 
for the use prior to IVT or mechanical thrombectomy as part of 
the current license, idarucizumab can be used according to its 
license for ‘patients in urgent need of intervention.’
There is a considerable number of case- reports (25 case reports 
including 31 patients) and one large case series (80 patients)52 
using idarucizumab prior to IVT. Table 3 provides an over-
view about currently available data from observational studies 
(bottom paragraph, ‘Idarucizumab’: 8 studies including 236 
patients) using idarucizumab, including national and hospital 
based data from continental Europe,52–55 New Zealand35 37 and 
Taiwan.56 Idarucizumab 5 g infusion was administered without 
waiting for confirmation of postreversal normalisation of 
coagulation profile. The New Zealand national reperfusion 
registry compared data of patients with dabigatran reversal to 
non- anticoagulated patients with almost identical risk of symp-
tomatic intracranial haemorrhage in dabigatran (3.8%) versus 
non- anticoagulated patients.35 However, idarucizumab is costly 
(approximately US$2400) and the cost–benefit of this approach 
in IVT is currently unknown; decision to treat such patients 
needs to be individualised.
Andexanet alfa is a novel antidote for factor Xa inhibitors 
and provides a rapid but non- permanent reversal of anticoag-
ulant effect. Andexanet alfa is given as a bolus and followed by 
a 2 hours infusion and anti- Xa activity is reduced by ~90%. 
However, a rebound of Xa activity occurs following completion 
of infusion. Treatment is associated with 10% early thrombotic 
complications. There is one recent case report describing the 
use of andexanet alfa prior to thrombolysis in a patient with 
ischaemic stroke and recent intake of apixaban without bleeding 
or thrombotic complications.57 The current price for andexanet 
alfa is approximately US$17 570. A calibrated anti- Xa level to 
assess DOAC activity costs about SFr45 in Switzerland (approx-
imately US$50).
MECHANICAL THROMBECTOMY
Data regarding safety and efficacy of mechanical thrombectomy 
in patients on DOAC rely on observational studies (table 4; 14 
studies with 558 patients). A recent meta- analysis, that also 
includes patients on VKA, concluded that patients on VKA 
(sOR 1.6, 95% CI 1.2 to 2.2), but not patients on DOAC (sOR 
1.0, 95% CI 0.6 to 1.8), had an increased risk of symptom-
atic intracranial haemorrhage after mechanical thrombectomy 
as compared with control patients without anticoagulation.48 
Major limitations of the studies included different rates of IVT 
(prior to mechanical thrombectomy), lack of reliable assessment 
of activity of DOAC, inclusion of patients with subtherapeutic 
DOAC, missing information on DOAC reversal as well as lack 
of adjustment for confounding. Nevertheless, the association 
with increased rates of symptomatic intracranial haemorrhage 
remained stable after including only studies with confirmed 
therapeutic VKA therapy (sOR 1.7, 95% CI 1.04 to 2.6) with 
no significant association for patients on confirmed therapeutic 
DOAC therapy (sOR 1.1, 95% CI 0.4 to 2.8). Additionally, 
after adjustments in a large observational study, the association 
of VKA with symptomatic intracranial haemorrhage (aOR 2.6, 
95% CI 1.3 to 4.8) remained tangible without a safety signal in 
patients on DOAC (aOR 0.9, 95% CI 0.3 to 3.3).
From a technical point of view, mechanical thrombectomy 
procedures seem feasible and successful in patients on DOAC. In 
a French multicentre observational study,58 an increased rate of 
successful reperfusion (modified treatment in cerebral ischemia 
score2b/3) in patients on DOAC as compared with patients on 
VKA (92.0% vs 74.3%, p 0.001) was reported. This was confirmed 
by another study showing that large vessel occlusion in patients 
on DOAC yielded excellent reperfusion rates as compared with 
VKA and controls (93.2% vs 81.5% vs 84.2%).48 The pathophys-
iology underlying this is unclear; however, potential differences in 
thrombus histology due to the different pharmacologic properties 
could explain these findings. The complication rates and procedure 
duration were comparable across the groups.48 58 All patients with 
large vessel occlusion qualifying for mechanical thrombectomy 
should be transferred to a centre where this procedure is available. 
Indication for IVT in patients on DOAC should not unnecessarily 
delay the transfer.
EXPERT OPINION-BASED APPROACH
Based on the available evidence, an individualised approach 
combining monitoring anticoagulant activity, imaging- based selec-
tion of patients most likely to benefit from acute recanalisation 
therapies (ie, mechanical thrombectomy for any large vessel occlu-
sion, IVT in the presence of potentially salvageable tissue) and the 
use of specific reversal agents only in selected patients seems the 
most promising approach. Figure 2 outlines these approaches.
FUTURE DIRECTIONS
Future research needs to elucidate the following aspects: first, 
availability of DOAC monitoring needs to be improved. Stream-
lining central laboratory measurement and reducing turn-
around times seem feasible.47 Point- of- care measurement for 
DOACs should be among the top priorities. Second, although 
prior reversal of anticoagulation using a specific reversal agent 
seems to be a reasonable and safe approach, health economics 
(pricing) and advanced imaging selection (salvageable tissue) 
given the relatively small effect size of thrombolysis on func-
tional outcome should be considered. It seems unlikely that this 
approach should be generalised to all patients. Furthermore, 
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other available approaches—using time since last intake and 
DOAC monitoring—seem to provide equally safety results.
Third, DOAC patients managed with IVT beyond the standard 
time thrombolysis window need to be explored. Fourth, although 
tenecteplase is not currently licensed for treatment of ischaemic 
stroke, several centres have reported off- label use of tenecteplase but 
experience of tenecteplase with DOAC pretreatment is limited.37
CONCLUSION
This review summarises current knowledge on recanalisation 
therapies for acute ischaemic stroke therapy in patients taking 
DOACs. Available data of >450 patients receiving IVT and 
>550 patients receiving mechanical thrombectomy provided 
reassuring safety results although only from observational studies 
and case reports and not randomised controlled trials. The use 
of IVT in patients with relative contraindications (eg, prior VKA 
therapy,59 60 dual antiplatelet therapy61 62 or epileptic seizures at 
onset63 has been studied with a focus on safety rather than effi-
cacy, probably due to an overall small effect size of thrombolysis 
in stroke and the need for large sample sizes to find any effect. 
We therefore urge caution that safe treatment is not equivalent 
to efficacy.
Even 10 years after introduction of the first DOAC on the 
market, there are still a lack of large, multicentre, multinational 
data with thorough documentation of selection criteria and 
safety and efficacy outcomes. A randomised controlled trial in 
the setting of thrombolysis in patients taking DOAC seems very 
unlikely. The results of large, prospective observational studies 
like registry of acute stroke under novel oral anticoagulants 
prime64 will hopefully provide further new insights in this topic 
and additional safety data.
Despite increasing experience and data availability in IVT for 
DOAC patients, the literature remains relatively limited. The 
small number of patients likely reflects the intrinsic bias to not 
treat with thrombolysis in patients on DOACs, and interpreta-
tion of the data therefore needs to be considered.
In summary, although available data provide promising and 
reassuring safety data, several aspects including patient selec-
tion need to be addressed in future studies. Precision medicine 
using a tailored approach combining monitoring anticoagulant 
activity, imaging- based selection (visualisation of potentially 
salvageable tissue) with potential use of specific reversal agents 
seems a reasonable choice in the interim.
REVIEW CRITERIA
We (DJS, TM, JK, DW and TYW) identified references for this 
review by searches of PubMed on 1 May 2020, 5 May 2020 
and 22 August 2020, using the search terms “(thrombolysis 
Table 4 Observational data on symptomatic intracerebral haemorrhage (sICH) risk following endovascular stroke treatment
Study




Number of patients 
(comparator)
Number of sICH/
rate Comment (DOAC group)
Heterogenous or unknown selection criteria (n=14 studies, n=558 patients)




Heterogenous selection criteria, all within 48 
hours, partly plasma level based.




All within 24 hours; PH1, PH2 and SAH defined 
as sICH.




No selection criteria or information on 
anticoagulation available.
  Purrucker et al44 28 (all DOAC) 1 (4%) NA Drug- specific coagulation tests indicated 
through drug concentrations in the majority of 
patients, no comparator.




No selection criteria or information on 
anticoagulation available.




No selection criteria or information on 
anticoagulation available.




No selection criteria or information on 
anticoagulation available, recall bias.




No selection criteria or information on 
anticoagulation available.
  Hoyer et al 10 (not specified) 0 (0%) 30 (no anticoagulation) 1 (3%) No selection criteria or information on 
anticoagulation available.




No selection criteria or information on 
anticoagulation available.




No selection criteria or information on 
anticoagulation available.




See below for patients with confirmed 
therapeutic DOAC therapy only.
  L’Allinec et al58 105 (all DOAC) 6 (6%) 97 (VKA) 12 (12%) Last intake within 24 hours, specific drug 
levels not available.




No selection criteria or information on 
anticoagulation available.
DOAC plasma- level based approach (n=2 studies, n=56 (patients))
  Seiffge et al28 7 (rivaroxaban) 0 (0%) NA 3 of 7 low or intermediate drug level




Ascertained compliance or therapeutic drug 
levels
DOAC, direct oral anticoagulant; PH, parenchymal haemorrhage; VKA, vitamin K antagonist.
copyright.
 on F














7Seiffge DJ, et al. J Neurol Neurosurg Psychiatry 2021;0:1–8. doi:10.1136/jnnp-2020-325456
Cerebrovascular disease
OR IVT OR rtPA OR tPA OR mechanical thrombectomy OR 
endovascular therapy OR MT OR EVT) AND (DOAC OR rivar-
oxaban OR dabigatran OR edoxaban OR apixaban OR DOAC 
OR direct oral anticoagulants OR novel oral anticoagulants OR 
Non- Vitamin K oral anticoagulants) AND (ischaemic stroke 
OR ischemic stroke)”. One author (DJS) additionally searched 
EMBASE and Web of science on 12 December 2020. We have 
excluded Betrixaban from our review due to limited availability 
outside the US and limited indication label. Additionally, we 
searched our personal records and abstracts from international 
conferences in the past 10 years (2010–2020) for relevant publi-
cations or data. We selected publications presenting original data 
and published in English if they reported ≥5 patients on DOACs 
who received recanalisation therapies. In addition, we searched 
PubMed, personal records and an internet search engine (ie, 
Google Scholar) using the search terms “guidelines”, “throm-
bolysis”, “stroke” and “oral anticoagulation” OR “DOAC” OR 
“direct oral anticoagulants” to identify guidelines from relevant 
organisations (national or international expert committees).
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